SCHEMBL22273595

SCHEMBL22273595

c1ccc2nc3c(nc2c1)oc1ccccc13

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LIMK1 P53667 1/20 0.40
NQO2 P16083 1/20 0.39
HPGD P15428 3/20 0.39
POLB P06746 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
ESR1 P03372 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
PTK2B Q14289 1/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
TP53 P04637 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24066629 0.98 MEN1 (0.41) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL27800007 0.85 ALDH1A1 (0.52) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26423372 0.82 ALDH1A1 (0.38) MEN1KMT2AKDM4EALDH1A1NQO2
SCHEMBL26423371 0.80 IDO1 (0.40) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL21176411 0.80 MEN1 (0.42) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL23327821 0.79 AHR (0.50) KDM4EALDH1A1SMN1; SMN2NQO2HPGD
SCHEMBL13907551 0.79 KMT2A (0.47) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL19876402 0.79 KMT2A (0.47) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL23327971 0.79 CA9 (0.43) MEN1KMT2AKDM4ESMN1; SMN2NQO2
SCHEMBL19887523 0.79 PLA2G2A (0.42) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10734589-B2 Organic compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2020-08-04 US claimed
US-20230127291-A1 HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127291-A1 HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL OCIAD2, OCIAD1, AZI2 MEN1 4289/4885KMT2A 3162/4885KDM4E 2800/4885
US-10734589-B2 Organic compound, light-emitting element, light-emitting device, electronic device, and lighting device AOX1, RECQL, SQOR MEN1 2051/4885KMT2A 853/4885KDM4E 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.